# [Consolidated Proposal] Next-Gen Drug Discovery Framework

## 1. Executive Summary
This proposal outlines a unified pipeline for accelerating lead discovery using state-of-the-art AI and molecular simulations. The framework is divided into two primary workflows: **Generative Discovery (DANOVO/Gatekeeper/DAPRE)** and **Gigascale Screening (SmartDTI)**.

## 2. The Generative Workflow
A target-specific design loop to create novel ligands for proprietary targets.

### Phase A: DANOVO (Molecule Generation)
- **Engine**: REINVENT 4 (Policy-based RL).
- **Function**: Exploring chemical space for novel binders.
- **Reference**: Loeffler et al. (2024), Blaschke et al. (2020).

### Phase B: SmartGatekeeper (Triage)
- **Logic**: Multi-view filtering (WHAT/HOW) using lightweight DTI models (GraphDTA/MolTrans).
- **Goal**: Reduce DANOVO output from $10^5$ to $10^2$ high-priority candidates.
- **Reference**: Wu et al. (2021), Kim & Kim (2025).

### Phase C: DAPRE (Validation)
- **Logic**: Physical-stability validation using Schrödinger (Docking/MM-GBSA) and 100ns+ MD simulations.
- **Final Score**: Neural affinity prediction via **Boltz-2**.
- **Reference**: Passaro et al. (2025).

---

## 3. The Screening Workflow (SmartDTI)
Massive exploration of external libraries to identify high-potential hits among billions of compounds.

### Strategy: Hierarchical Machine Learning Screening
- **Level 1**: Gigascale pre-screening (Deep Docking style) using GIN/GraphDTA.
- **Level 2**: Hierarchical heterogeneous graph learning (**H2GnnDTI**).
- **Level 3**: Multi-view integration (**MVGCN**) to fuse topological and biological network data.
- **Level 4**: 3D spatial pocket refinement using **Uni-Mol/Uni-Mol+**.

### Data Sources:
- **Training**: DAVIS, KIBA, PDBbind, BindingDB, ChEMBL, BioSNAP.
- **Screening Library**: Enamine REAL, ZINC-22.

---

## 4. Technical Rigor & Scientific Justification
- **Equivariance & 3D Awareness**: Utilizing SE(3)-equivariant transformers (Uni-Mol) to move beyond residue-level approximations.
- **Interpretability**: Cross-attention heatmaps for binding site analysis.
- **Generalizability**: Rigorous "Cold-Drug" and "Cold-Target" validation splits.

*Authored by Antigravity R&D Agent*
